Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection

Treatment of chronic viral infections accompanied by permanent virus persistence in the target epitopes of the oral cavity, skin, urogenital tract is complicated by virtual lack of available drugs exerting combined systemic virulicidal and immunomodulatory effects. Here we demonstrate clinical and i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: V. A. Zurochka, O. I. Zabkov, M. A. Dobrynina, V. F. Gritsenko, E. V. Davydova, A. V. Chukichev, N. A. Zabokritskii, A. P. Sarapultsev, A. V. Zurochka
Formato: article
Lenguaje:RU
Publicado: Sankt-Peterburg : NIIÈM imeni Pastera 2020
Materias:
Acceso en línea:https://doaj.org/article/6f8ae2a011984f6db0e2e33dd0e78757
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6f8ae2a011984f6db0e2e33dd0e78757
record_format dspace
spelling oai:doaj.org-article:6f8ae2a011984f6db0e2e33dd0e787572021-11-22T07:09:53ZClinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection2220-76192313-739810.15789/2220-7619-CDC-1141https://doaj.org/article/6f8ae2a011984f6db0e2e33dd0e787572020-05-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1141https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398Treatment of chronic viral infections accompanied by permanent virus persistence in the target epitopes of the oral cavity, skin, urogenital tract is complicated by virtual lack of available drugs exerting combined systemic virulicidal and immunomodulatory effects. Here we demonstrate clinical and immunological efficacy of combined therapy in treatment of Epstein–Barr virus (EBV)-associated chronic infections. The aim of the study was to evaluate the clinical and immunological efficacy of combined etiopathogenetic therapy using the Acegram cosmetic product in patients with EBV-associated chronic infections. Materials and methods. There were enrolled 40 patients monitored before treatment as well as 20 patients followed up after combination therapy (cycle therapy consisted of oral valaciclovir (Valtrex) applied at dose of 500 μg twice a day for 10 days, glucosaminylmuramyldipeptide (Licopid) — 10 mg 2 twice a day for 10 days, topical irrigation for mucous membranes with granulocyte-macrophage colony-stimulating factor active center-derived peptide (Acegram-spray) 3 times a day for 10 days. If necessary, treatment courses were repeated 20 days after the onset. All patients were examined for the presence of EBV genomes in the oral fluid and blood using the qualitative and quantitative polymerase chain reaction (PCR) using the DNA technology test system (Russia) on a DT-Lite device prior treatment and 30, 60 days post-therapy time points. In addition, serum samples were analyzed for level of class G immunoglobulins specific to the EBV nuclear and capsid antigens by using enzyme immunoassay (test systems manufactured by CJSC Vector Best, Russia) as well as immune status (clinical methods, enu flow cytometry evaluation of the phagocytic activity of neutrophils, ELISA method). Results. Use of single or two course combination therapy in subjects with fully eradicated EBV carriage associated with reversed clinical symptoms was accompanied by recovered immune system status (T and B cells, T-helper cells, CD3+ CD25+  cells, phagocytosis parameters). A non-invasive approach proposed for controlling virus elimination in the oral fluid by using polymerase chain reaction method may serve as to objectively monitor therapeutic efficacy.V. A. ZurochkaO. I. ZabkovM. A. DobryninaV. F. GritsenkoE. V. DavydovaA. V. ChukichevN. A. ZabokritskiiA. P. SarapultsevA. V. ZurochkaSankt-Peterburg : NIIÈM imeni Pasteraarticleepstein–barr virus infectionvalacyclovirglucosaminilmuramildipeptidecosmetic “acegram”antiviral activityflow cytometryenzyme-linked immunosorbent assaypolymerase chain reactionlymphocytesimmune statusInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 10, Iss 2, Pp 338-346 (2020)
institution DOAJ
collection DOAJ
language RU
topic epstein–barr virus infection
valacyclovir
glucosaminilmuramildipeptide
cosmetic “acegram”
antiviral activity
flow cytometry
enzyme-linked immunosorbent assay
polymerase chain reaction
lymphocytes
immune status
Infectious and parasitic diseases
RC109-216
spellingShingle epstein–barr virus infection
valacyclovir
glucosaminilmuramildipeptide
cosmetic “acegram”
antiviral activity
flow cytometry
enzyme-linked immunosorbent assay
polymerase chain reaction
lymphocytes
immune status
Infectious and parasitic diseases
RC109-216
V. A. Zurochka
O. I. Zabkov
M. A. Dobrynina
V. F. Gritsenko
E. V. Davydova
A. V. Chukichev
N. A. Zabokritskii
A. P. Sarapultsev
A. V. Zurochka
Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
description Treatment of chronic viral infections accompanied by permanent virus persistence in the target epitopes of the oral cavity, skin, urogenital tract is complicated by virtual lack of available drugs exerting combined systemic virulicidal and immunomodulatory effects. Here we demonstrate clinical and immunological efficacy of combined therapy in treatment of Epstein–Barr virus (EBV)-associated chronic infections. The aim of the study was to evaluate the clinical and immunological efficacy of combined etiopathogenetic therapy using the Acegram cosmetic product in patients with EBV-associated chronic infections. Materials and methods. There were enrolled 40 patients monitored before treatment as well as 20 patients followed up after combination therapy (cycle therapy consisted of oral valaciclovir (Valtrex) applied at dose of 500 μg twice a day for 10 days, glucosaminylmuramyldipeptide (Licopid) — 10 mg 2 twice a day for 10 days, topical irrigation for mucous membranes with granulocyte-macrophage colony-stimulating factor active center-derived peptide (Acegram-spray) 3 times a day for 10 days. If necessary, treatment courses were repeated 20 days after the onset. All patients were examined for the presence of EBV genomes in the oral fluid and blood using the qualitative and quantitative polymerase chain reaction (PCR) using the DNA technology test system (Russia) on a DT-Lite device prior treatment and 30, 60 days post-therapy time points. In addition, serum samples were analyzed for level of class G immunoglobulins specific to the EBV nuclear and capsid antigens by using enzyme immunoassay (test systems manufactured by CJSC Vector Best, Russia) as well as immune status (clinical methods, enu flow cytometry evaluation of the phagocytic activity of neutrophils, ELISA method). Results. Use of single or two course combination therapy in subjects with fully eradicated EBV carriage associated with reversed clinical symptoms was accompanied by recovered immune system status (T and B cells, T-helper cells, CD3+ CD25+  cells, phagocytosis parameters). A non-invasive approach proposed for controlling virus elimination in the oral fluid by using polymerase chain reaction method may serve as to objectively monitor therapeutic efficacy.
format article
author V. A. Zurochka
O. I. Zabkov
M. A. Dobrynina
V. F. Gritsenko
E. V. Davydova
A. V. Chukichev
N. A. Zabokritskii
A. P. Sarapultsev
A. V. Zurochka
author_facet V. A. Zurochka
O. I. Zabkov
M. A. Dobrynina
V. F. Gritsenko
E. V. Davydova
A. V. Chukichev
N. A. Zabokritskii
A. P. Sarapultsev
A. V. Zurochka
author_sort V. A. Zurochka
title Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
title_short Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
title_full Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
title_fullStr Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
title_full_unstemmed Clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic Epstein–Barr virus infection
title_sort clinical diagnostic criteria of efficiency for combined etiopathogenetic therapy in patients with chronic epstein–barr virus infection
publisher Sankt-Peterburg : NIIÈM imeni Pastera
publishDate 2020
url https://doaj.org/article/6f8ae2a011984f6db0e2e33dd0e78757
work_keys_str_mv AT vazurochka clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection
AT oizabkov clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection
AT madobrynina clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection
AT vfgritsenko clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection
AT evdavydova clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection
AT avchukichev clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection
AT nazabokritskii clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection
AT apsarapultsev clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection
AT avzurochka clinicaldiagnosticcriteriaofefficiencyforcombinedetiopathogenetictherapyinpatientswithchronicepsteinbarrvirusinfection
_version_ 1718417922820407296